(provided by candidate): Dr. Jennifer Yearley graduated with her DVM degree from Washington State University College of Veterinary Medicine in 2001, and completed training in veterinary anatomic pathology at the NEPRC in July of 2006. She was involved with studies of bacterial pathogenesis while in veterinary school, and has been working in animal models of lentiviral pathogenesis and AIDS since 2002. Dr. Yearley's research at the NEPRC has centered on the pathogenesis of cardiomyopathy in the context of SIV/HIV infection, and this work forms the basis of her present doctoral studies. Dr. Yearley ultimately intends an academic research career examining the role of inflammation in cardiovascular disease. Cardiomyopathy occurs at much higher rates among HIV-infected people than in the general population and preliminary studies conducted at the NEPRC using the SIV-model of HIV infection, have implicated exaggerated Myocardial inflammatory cytokine responsiveness to stimulation with ubiquitous agents known to engage toll-like receptor 2 (TLR2) as important contributory factors to development of cardiac dysfunction. Based on these findings, we hypothesize that HIV-infected individuals show increased TLR2 expression and/or amplified TLR2-mediated signal transduction on myocardial cell populations, with resulting enhancement of cardiac inflammatory cytokine responses and subsequent ventricular dysfunction, pathological structural remodeling, and ultimately heart failure. To address the predictions made by this hypothesis, in our first aim we will subject SIV-infected rhesus monkeys to long-term, systemic stimulation with heat-inactivated Mycobacterium avium, assessing myocardial TNFalpha, IL-1beta, and IL-18 mRNA and protein levels, and correlating systemic and myocardial cytokine levels with the development and progression of cardiac dysfunction and remodeling. In our second aim, we will characterize the relationship between levels of TLR2 expression and systemic and myocardial inflammatory cytokine production in response to TLR2 stimulation in the context of SIV infection. In our third aim, we will characterize differences in inflammatory signal transduction pathway activation in SIV/HIV infection in response to TLR2 ligation. The NEPRC is an outstanding environment for research training, with superb facilities, unique resources, and world-class researchers, providing a rigorous context for pursuit of scientific investigation. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01RR024120-02
Application #
7393248
Study Section
Special Emphasis Panel (ZRR1-CM-9 (02))
Program Officer
Moro, Manuel H
Project Start
2007-04-06
Project End
2008-07-12
Budget Start
2008-04-01
Budget End
2008-07-12
Support Year
2
Fiscal Year
2008
Total Cost
$123,093
Indirect Cost
Name
Harvard University
Department
Veterinary Sciences
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Jensen, J T; Edelman, A B; Chen, B A et al. (2018) Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study. Contraception 97:422-427
Samuels, Mary H; Kolobova, Irina; Niederhausen, Meike et al. (2018) Effects of Altering Levothyroxine Dose on Energy Expenditure and Body Composition in Subjects Treated With LT4. J Clin Endocrinol Metab 103:4163-4175
Edelman, Alison B; Cherala, Ganesh; Li, Hong et al. (2017) Levonorgestrel butanoate intramuscular injection does not reliably suppress ovulation for 90 days in obese and normal-BMI women: a pilot study. Contraception 95:55-58
Samuels, Mary H; Kolobova, Irina; Antosik, Megan et al. (2017) Thyroid Function Variation in the Normal Range, Energy Expenditure, and Body Composition in L-T4-Treated Subjects. J Clin Endocrinol Metab 102:2533-2542
Edelman, Alison B; Cherala, Ganesh; Blue, Steven W et al. (2016) Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing. Contraception 94:52-7
Samuels, Mary H; Kolobova, Irina; Smeraglio, Anne et al. (2016) Effects of Levothyroxine Replacement or Suppressive Therapy on Energy Expenditure and Body Composition. Thyroid 26:347-55
Cherala, Ganesh; Edelman, Alison (2015) How can we improve oral contraceptive success in obese women? Expert Rev Clin Pharmacol 8:1-3
Cherala, Ganesh; Pearson, Jacob; Maslen, Cheryl et al. (2014) An ethinyl estradiol-levonorgestrel containing oral contraceptive does not alter cytochrome P4502C9 in vivo activity. Drug Metab Dispos 42:323-5
Holbein, M E Blair; Berglund, Jelena Petrovic; O'Reilly, Erin K et al. (2014) Recommendations from the Investigational New Drug/Investigational Device Exemption Task Force of the clInical and Translational Science Award Consortium: developing and implementing a sponsor-investigators training program. J Investig Med 62:797-803
Edelman, Alison B; Cherala, Ganesh; Munar, Myrna Y et al. (2014) Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. Contraception 90:550-6

Showing the most recent 10 out of 29 publications